“Previously, this mutation has been undruggable, but this is now changing.”
For this episode of “The Vitals,” we spoke with Kristin Barber, FNP-BC, AOCNP, Huntsman Cancer Institute, about understanding the MAP kinase signaling pathway and some of the ongoing trials targeting these mutations in gastrointestinal oncology.
Barber discussed some of the ongoing phase 1 trials she is participating in and how she hopes the results of these trials could change patient outcomes following targeted treatment.
ODAC Votes To Continue Dostarlimab Research in dMMR/MSI-H Locally Advanced Rectal Cancer
February 12th 2023In an 8 to 5 vote, ODAC voted in support of launching 2 single-arm trials seeking to characterize the risk-benefit profile of dostarlimab for patients with dMMR/MSI-H locally advanced rectal cancer.
Lenvatinib Plus Pembrolizumab Elicits Durable Responses in Patients With Endometrial Cancer
Carolina Frailty Index Score May Be Applicable in Assessment of Patients with Ovarian Cancer
GCLQ and LELSQ Show Concordance in Assessment of Lymphedema in Patients With Endometrial Cancer
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
2 Clarke Drive
Cranbury, NJ 08512